Genetic study of Alport syndrome in Tunisia
Pediatric Nephrology · 2025-01 · 40 (1) · 103-116
DOI: 10.1007/s00467-024-06474-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Nephrology, online erschienen am 14.08.2024. Verfasst von Mariem El Younsi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Génétique Humaine, Faculté de Médecine de Tunis, Université de Tunis El Manar, LR99ES101007, Tunis, Tunisia. Hauptthemen laut MEDLINE: Nephritis, Hereditary, Collagen Type IV, Autoantigens, Exome Sequencing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Alport syndrome is a genetic disorder affecting the kidneys, ears, and eyes, causing chronic kidney disease, sensorineural hearing loss, and ocular abnormalities. It results from pathogenic variants in the COL4A3, COL4A4, or COL4A5 genes, with different inheritance patterns: X-linked from COL4A5 variants, autosomal recessive from homozygous variants in COL4A3 or COL4A4, digenic from variants in both COL4A3 and COL4A4, and autosomal dominant from heterozygous variants in COL4A3 or COL4A4. METHODS: We analyzed 45 patients with Alport syndrome from 11 Tunisian families to determine their clinical and genetic characteristics. Clinical data were collected retrospectively, and whole-exome sequencing was conducted on one patient from each family. Sanger sequencing validated pathogenic variants, and cascade screening extended the analysis to 53 individuals. RESULTS: We identified nine likely pathogenic variants among 11 index cases: six novel and three known variations. Of these, five were in COL4A3, and four were in COL4A5, with variants including frameshift, nonsense, missense, and alternative splicing. Most variations affected the Gly-XY codon. Among the 45 clinically identified siblings, 30 tested positive for Alport syndrome. The cascade screening identified 3 additional affected individuals, 10 unaffected siblings, and 10 unaffected parents. The mode of inheritance was autosomal recessive in six families and X-linked in four families. CONCLUSIONS: This study is the first to screen the mutational spectrum of Alport syndrome in Tunisia. It reveals novel pathogenic variants and suggests that autosomal recessive inheritance may be more common in the Tunisian population than X-linked inheritance, contrary to existing literature.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratoire de Génétique Humaine, Faculté de Médecine de Tunis, Université de Tunis El Manar, LR99ES101007, Tunis, Tunisia.
- Service des Maladies Congénitales Et Héréditaires, Hôpital Charles Nicolle, 1006, Tunis, Tunisia.
- Laboratory of Biomedical Genomics and Oncogenetics, Pasteur Institute of Tunis, 1002, Tunis, Tunisia.
- Service de Néphrologie Pédiatrique, Hôpital Charles Nicolle, 1006, Tunis, Tunisia.
- Service de Médecine Interne Et de Néphrologie Adulte, Hôpital Charles Nicolle, 1006, Tunis, Tunisia.
- Service Néphrologie, L'Hôpital Militaire Principal d'Instruction de Tunis, MontFleury, 1008, Tunis, Tunisia.
Zitieren
APA
Younsi, M. E., Achour, A., Kraoua, L., Nesrine, M., Sayari, T., Abderrahim, E., Laabidi, J., Zouaghi, M. K., Kharrat, M., Gargah, T., Trabelsi, M., & M'rad, R. (2025). Genetic study of Alport syndrome in Tunisia. Pediatric Nephrology, 40(1), 103-116. https://doi.org/10.1007/s00467-024-06474-7
Vancouver
Younsi ME, Achour A, Kraoua L, Nesrine M, Sayari T, Abderrahim E, et al. Genetic study of Alport syndrome in Tunisia. Pediatric Nephrology. 2025;40(1):103-116. doi:10.1007/s00467-024-06474-7
BibTeX
@article{Younsi2025,
author = {Younsi, Mariem El and Achour, Ahlem and Kraoua, Lilia and Nesrine, Mezzi and Sayari, Taha and Abderrahim, Ezzeddine and Laabidi, Janet and Zouaghi, Mohamed Karim and Kharrat, Maher and Gargah, Tahar and Trabelsi, Mediha and M'rad, Ridha},
title = {Genetic study of Alport syndrome in Tunisia},
journal = {Pediatric Nephrology},
year = {2025},
volume = {40},
number = {1},
pages = {103--116},
doi = {10.1007/s00467-024-06474-7}
}
EUVIMED